# Samsara BioCapital

Samsara BioCapital is a Private Equity based in Palo Alto, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Palo Alto, United States
- **Region:** North America
- **Address:** 628 Middlefield Road, Palo Alto, CA 94301, United States
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** www.samsaracap.com
- **LinkedIn:** https://www.linkedin.com/company/samsara-biocapital

## Regulatory record

- **CRD number:** 288114
- **SEC file number:** 801-113741
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/288114

## About

Samsara BioCapital invests to create transformative therapeutics for patients. The firm brings together scientists, physicians, drug developers, and business leaders with over 500 years of combined experience to back the next generation of therapeutic breakthroughs.

## Sectors

- Digital Health
- Healthcare Services
- Platform

## People

- Srini Akkaraju — Founder & Managing General Partner

## Questions

### Who runs investment decisions at Samsara BioCapital?

Dr. Srinivas Akkaraju, the Founder and Managing General Partner, leads investment decisions. He is supported by partners Mike Dybbs and Abe Bassan, and a deep bench of venture partners — including former CFOs and R&D heads from BioMarin, Genentech, and other biopharma companies — who contribute to due diligence and portfolio-company oversight.

### What investment stages does Samsara BioCapital typically target?

The firm targets the full biotech lifecycle: seed-stage company creation, early-stage venture rounds, expansion and late-stage financings, and public-company positions. Its portfolio includes recent IPOs such as Arcellx and Prime Medicine, as well as preclinical and clinical-stage private companies such as Kalaris Therapeutics and Tentarix Biotherapeutics.

### Which sectors does Samsara BioCapital explicitly avoid?

Samsara does not publish a formal exclusion list. Its portfolio is concentrated almost entirely on human therapeutics — spanning oncology, immunology, cardiometabolic, gene therapy, and ophthalmology — with limited exposure to diagnostics and digital health. Non-therapeutic sectors such as medical devices or healthcare IT appear absent from the disclosed portfolio.

## Related profiles

- [Samruk-Kazyna](https://altss.com/profile/samruk-kazyna-national-welfare-fund)
- [Samsara Holdings](https://altss.com/profile/samsara-holdings)

---

Last updated: 2026-08-11T15:08:04.536Z

Canonical page: https://altss.com/profile/samsara-biocapital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology